
Ultraprocessed food linked to early signs of Parkinson's disease, study says
See all topics
Eating about a dozen servings of ultraprocessed food each day could more than double your risk of developing Parkinson's disease, according to a new study.
A single serving in the study was 8 ounces of diet or sugar-sweetened soda, a single hot dog, one slice of packaged cake, a mere tablespoon of ketchup or 1 ounce of potato chips — a typical small bag of chips is 1.5 ounces.
'Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease,' said senior study author Dr. Xiang Gao, a distinguished professor and dean of the Institute of Nutrition at Fudan University in Shanghai, China, in a statement.
This latest study is part of the 'growing evidence that diet might influence the development of Parkinson's disease,' Gao said.
While the study found that people who ate more ultraprocessed foods tended to report more early symptoms, it did not find a direct increase in the risk of Parkinson's disease itself, said Dr. Daniel van Wamelen, a clinical senior lecturer in neuroscience at King's College London. He was not involved in the new research.
'The study did not track whether participants were diagnosed with Parkinson's later on,' van Wamelen said in a statement. 'That said, having more of these symptoms suggests a higher risk over time.'
The study analyzed years of health and diet data on nearly 43,000 participants of the Nurses' Health Study and Health Professionals Follow-Up Study, two studies in the United States that have been gathering information on health behaviors for decades. The average age of people in the study was 48, and none had Parkinson's disease at the beginning of the study. All self-reported what they ate every few years — a limitation of the new research as participants may not have remembered their food intake accurately.
Ultraprocessed foods measured by the study included artificially or sugar-sweetened beverages; condiments, sauces and spreads; packaged sweets snacks or desserts; yogurt or dairy-based desserts; breads and cereals; and packaged savory snacks.
The study found a link between early signs of Parkinson's disease and all types of ultraprocessed foods except breads and cereals — a finding that indicates an underlying feature among most classes of ultraprocessed foods that may explain the results, the study said.
One reason could be ultraprocessed foods typically have less dietary fiber, protein and micronutrients — but do have added sugar, salt, and saturated or trans fats, the study said. Ultraprocessed foods also may impact the balance of flora in the gut, while additives may increase inflammation, free radicals and neuron death, the study said.
'With a sample size exceeding 42,800 participants and a long follow-up period up to 26 years, this study stands out not only for its power but also for its methodological rigor,' wrote the authors of a corresponding editorial published with the study.
The editorial was coauthored by Dr. Nikolaos Scarmeas, an associate professor of clinical neurology at Columbia University in New York City, and dietitian Maria Maraki, an assistant professor of sports medicine and exercise biology at the National and Kapodistrian University of Athens, Greece. Neither were involved in the new research.
'The prevention of neurodegenerative diseases may begin at the dinner table,' they wrote. 'Excessive UPF consumption not only is a risk factor for metabolic diseases but may also accelerate neurodegenerative processes and associated symptoms.'
In the new study, published Wednesday in the journal Neurology, researchers looked at the prodromal stage of Parkinson's disease — early signals that appear years to decades before the tremors, stiff muscles, slow gait and changes in posture that are hallmark symptoms of Parkinson's.
Body pain, constipation, signs of depression, changes in the ability to smell or see colors, and excessive daytime sleepiness can all be early signs of Parkinson's disease, according to the Parkinson's Foundation.
An extremely unusual sleep disorder, in which people can move during REM, or the rapid eye movement stage of sleep, is also a key early sign, according to research. The body is typically paralyzed during REM sleep so it cannot get up and act out any dreams.
The study found that people who ate about 11 servings a day of ultraprocessed food — compared to people who only ate three — had a 2.5-fold greater likelihood of exhibiting three or more of the early signs of Parkinson's.
In addition, eating more ultraprocessed foods was tied to an increased risk for nearly all symptoms except constipation, according to the study. This finding held true even after researchers accounted for other factors, such as age, physical activity and smoking, that might impact the results.
'Parkinson's is an incurable disease,' Gao said in an email. 'In our previous study based on the same populations used for the current analysis, we found that a healthy dietary pattern and physical activity could slow the disease progression.
'Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health.'
Sign up for CNN's Eat, But Better: Mediterranean Style. Our eight-part guide shows you a delicious expert-backed eating lifestyle that will boost your health for life .
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@
Yahoo
12 hours ago
- Yahoo
Gut bacteria changes could be ‘warning sign for worsening Parkinson's symptoms'
Changes in specific bacteria in the mouth and gut of patients with Parkinson's disease could potentially be an early warning sign that symptoms of the condition are getting worse, a study suggests. With the help of artificial intelligence (AI), scientists have linked these shifts to cognitive decline – problems with memory and learning – in people with the disease. They suggest the toxins could one day be used as 'markers' for medics to pinpoint the Parkinson's patients at a higher risk of dementia, as well as being used to help develop targeted treatments for the disease. Parkinson's disease is a progressive condition that affects the brain, with symptoms including involuntary shaking, known as tremors, as well as psychological problems such as depression, loss of balance, trouble sleeping and memory issues. According to the Alzheimer's Society, around a third of people with Parkinson's eventually develop dementia. Dr Saeed Shoaie, group leader of the quantitative systems biology (QTS) lab at King's College London, said: 'The human gut and oral bacterial communities are increasingly linked to neurodegenerative diseases. 'Disruptions in the gut-brain axis could trigger inflammation and immune responses that contribute to neuronal damage. 'A common gum disease bacterium like porphyromonas gingivalis has been discovered as a potential driver of Alzheimer's.' For the study, led by experts at King's College London and published in the journal Gut Microbes, scientists analysed 228 spit and stool samples. The samples came from 41 patients with Parkinson's and mild cognitive impairment, which causes problems with thinking and memory, 47 patients with Parkinson's and dementia and 26 healthy patients. The team found that the gut of people with mild cognitive impairment contained more harmful bacteria, many of which are likely to have come from the mouth. This bacteria releases toxins that can damage gut tissue, promote inflammation and potentially affect the brain, according to researchers. For a more in-depth analysis, the team used AI to pinpoint the bacterial species and functions not usually picked up by traditional testing, allowing them to link toxins specifically to cognitive decline. Dr Shoaie added: 'The emerging evidence underscores the potential importance of maintaining oral and gut health in mitigating or slowing neurodegenerative processes. 'As people with Parkinson's become increasingly reliant on carers, routine practices such as oral hygiene and nutritional intake may be neglected. 'Our findings suggest that promoting a healthy microbiome through consistent oral care, a balanced diet and potentially targeted probiotic interventions could support improved disease management in Parkinson's.' Dr Frederick Clasen, research associate at the QTS lab, said: 'We don't yet know if the bacteria are causing the cognitive decline or if changes in the body due to Parkinson's allow these bacteria to grow. 'But our findings suggest they may play an active role in worsening symptoms.' Dr Clasen suggests these markers could one day be used to develop targeted treatments. 'These toxins could be used as biological markers to identify patients at higher risk of dementia in Parkinson's,' he said. 'In the future, they might also be targets for new treatments that protect the brain by changing the gut environment.'


New York Post
15 hours ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.